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Cochrane Collaborative Review Group on Peripheral Vascular
Diseases: Review AbstractsIntroduction
The following abstracts are part of an ongoing series
of articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases, which
is part of The Cochrane Collaboration. The reviews
are published in full in The Cochrane Database of Sys-
tematic Reviews in The Cochrane Library, a quarterly
electronic journal available on CD-ROM and via the
Internet. The electronic format allows Cochrane re-
views to accommodate new data as they become avail-
able, making the library a consistently up-to-date
source of information over time.
Certain abstracts appearing in The Cochrane Database
of Systematic Reviewsmay be presented in a simpler, less
scientific format than the abstract presented here to
permit greater accessibility to the public. However,
the substance of both versions is the same. Cochrane
reviews are now indexed on MEDLINE.
If you are interested in conducting a Cochrane re-
view or contributing to the activities of the Cochrane
Collaborative Review Group on Peripheral Vascular
Diseases, please contact:
Professor FGR Fowkes






Tel.: þ44 (0) 131 650 3220
Fax: þ44 (0) 131 650 6904
Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/crit-
icisms facility on The Cochrane Library, or by contacting
the group at the above address.1078–5884/000383+ 03 $32.00/0  2007 Published by Elsevier Ltd onAbstracts
Abstract. Cilostazol for peripheral arterial disease
Robless P, Mikhailidis DP, Stansby GP
The Cochrane Database of Systematic Reviews Pub-
lished in Issue 1, 2007
Background
Peripheral arterial disease (PAD) affects 4% to 12% of
people aged 55 to 70 years and 20% of people over 70
years. The most common complaint is intermittent
claudication (IC) characterised by pain in the legs or
buttocks that occurs with exercise and which subsides
with rest. Compared with age-matched controls, peo-
ple with IC have a three- to six-fold increase in cardio-
vascular mortality. Symptoms of IC, walking distance,
and quality of life can be improved by risk factor mod-
ification, smoking cessation, and a structured exercise
program. Antiplatelet treatment is beneficial in pa-
tients with IC for the reduction of vascular events but
has not been shown to influence claudication distance.
Objectives
To determine the effect of cilostazol on improving
walking distance and in reducing vascular mortality
and cardiovascular events in patients with stable IC.
Search Strategy
The Cochrane Peripheral Vascular Diseases Group
searched their specialised register (last searched
August 2006) and the Cochrane Central Register of
Controlled Trials (CENTRAL) (Issue 3, 2006). We
searched MEDLINE (1966 to November 2005),behalf of European Society for Vascular Surgery.
384 Cochrane Review AbstractsEMBASE (1980 to November 2005), several more spe-
cialised databases, and reference lists of articles.
Selection Criteria
Double-blind, randomised controlled trials of cilosta-
zol versus placebo, or versus other antiplatelet agents
in patients with stable IC or patients undergoing
vascular surgical intervention for PAD.
Data Collection and Analysis
Two authors independently assessed trials for selec-
tion and all three authors independently extracted
data.
Main Results
Eight randomised controlled trials comparing cilosta-
zol with placebo were included.
The weighted mean difference (WMD) for the ini-
tial claudication distance (ICD) was improved follow-
ing treatment with cilostazol 100 mg twice daily
(WMD 31.1 m; 95% confidence interval (CI): 21.4 to
40.9 m) and 50 mg twice daily (WMD 41.3 m; 95%
CI: 7.1 to 89.7 m) compared with placebo.
Participants receiving cilostazol 150 mg twice daily
had an increased ICD (WMD 15.7 m; 95% CI: 9.6 to
41.0 m) compared with those receiving placebo.
One study also included a comparison with pen-
toxifylline. In this study, participants receiving cilosta-
zol had significant improvement in ICD compared
with placebo.
There was no increase in major adverse events in-
cluding cardiovascular events or mortality in patients
receiving cilostazol compared with placebo.
Authors’ Conclusions
Patients with IC should receive secondary prevention
for cardiovascular disease. Cilostazol has been shown
to be of benefit in improving walking distance in peo-
ple with IC. There are no data on whether it results in
a reduction of adverse cardiovascular events.
Abstract. Endovascular treatment for ruptured
abdominal aortic aneurysm
Dillon M, Cardwell C, Blair PH, Ellis P, Kee F,
Harkin DW
The Cochrane Database of Systematic Reviews
Published in Issue 1, 2007
Eur J Vasc Endovasc Surg Vol 34, October 2007Background
An abdominal aortic aneurysm (AAA) (the patholog-
ical enlargement of the aorta) can develop in both men
and women as they grow older. It is most commonly
seen in men over the age of 65 years. Progressive an-
eurysm enlargement can lead to rupture and massive
internal bleeding, a fatal event unless timely repair
can be achieved. Despite improvements in periopera-
tive care, mortality remains high (approximately 50%)
after conventional open surgical repair. A newer min-
imally invasive technique, endovascular repair, has
been shown to reduce early morbidity and mortality,
as compared to conventional open surgery, for
planned AAA repair. Emergency endovascular repair
(eEVAR) has been used successfully to treat ruptured
abdominal aortic aneurysm (RAAA), proving that it is
feasible in selected patients. However, it is not yet
known if eEVAR will lead to significant improve-
ments in outcomes for these patients or indeed if it
can replace conventional open repair as the preferred
treatment for this lethal condition.
Objectives
To compare the advantages and disadvantages of
eEVAR in comparison with conventional open surgi-
cal repair for the treatment of RAAA.
Search Strategy
The Cochrane Peripheral Vascular Diseases Group
searched their trials register (last searched October
2006) and the Cochrane Central Register of Controlled
Trials (CENTRAL) database (last searched Issue 4,
2006). We searched a number of electronic databases
and handsearched relevant journals until March
2006 to identify studies for inclusion.
Selection Criteria
Randomised controlled trials in which patients with
a confirmed ruptured abdominal aortic aneurysm
were randomly allocated to eEVAR, or conventional
open surgical repair.
Data Collection and Analysis
Studies identified for potential inclusion were inde-
pendently assessed for eligibility by at least two
reviewers, with excluded studies further checked by
the agreed arbitrators. As no randomised controlled
385Cochrane Review Abstractstrials were identified at present no tests of heterogene-
ity or sensitivity analysis were performed.
Main Results
There were no randomised controlled trials identified
at present comparing eEVAR with conventional open
surgical repair for the treatment of RAAA.
Authors’ Conclusions
There is no high quality evidence to support the use of
eEVAR in the treatment of RAAA. However, evidence
from prospective controlled studies without random-
isation, prospective studies, and retrospective case
series suggest that eEVAR is feasible in selected pa-
tients, with outcomes comparable to best conventional
open surgical repair for the treatment of RAAA. Fur-
thermore, endovascular repair in selected patients
may be associated with a trend towards reductions
in blood loss, duration of intensive care treatment,
and mortality.
Abstract. Treatment for superficial thrombophle-
bitis of the leg
Di Nisio M, Middeldorp S, Wichers IM
The Cochrane Database of Systematic Reviews
Published in Issue 1, 2007
Background
The optimal treatment of superficial thrombophlebitis
(ST) of the legs remains poorly defined. While improv-
ing or relieving the local painful symptoms, treatment
should aim at preventing venous thromboembolism
(VTE),whichmight complicate thenaturalhistoryof ST.
Objectives
To assess the efficacy and safety of topical, medical,
and surgical treatments in patients presenting with
ST of the legs.
Search Strategy
The Cochrane Peripheral Vascular Diseases Group
searched their specialized register (last searched
October 2006), and the Cochrane Central Register of
Controlled Trials (CENTRAL) (last searched Issue 4,
2006. We searched MEDLINE (1966 to January 2006),
EMBASE (1980 to January 2006), and handsearchedreference lists of relevant papers and conference
proceedings.
Selection Criteria
Randomized trials evaluating topical, medical, and
surgical treatments for ST of the leg including partic-
ipants with a clinical diagnosis of ST of the legs or ob-
jective diagnosis of a thrombus in the superficial vein.
Data Collection and Analysis
Two authors assessed the trials for inclusion in the re-
view, extracted the data, and assessed the quality of
the studies. Data were extracted independently from
the included studies and any disagreements resolved
by consensus.
Main Results
Twenty-four studies involving 2469 participants with
ST of the legs were included in this review. The meth-
odological quality of most of the trials was poor. Treat-
ment ranged from low molecular weight heparin
(LMWH), to non-steroidal anti-inflammatory agents
(NSAIDs), topical treatment, surgery, oral, intramus-
cular, and intravenous treatments. Both LMWH and
NSAIDs significantly reduced the incidence of ST ex-
tension or recurrences by about 70% compared with
placebo and both seemed to have a similar efficacy
and safety. Overall, topical treatments improved local
symptoms. However, no data were provided on the
effects of these treatments on VTE and ST extension.
Surgical treatment combined with elastic stockings
in ST was associated with a lower VTE rate and ST
progression, compared with elastic stockings alone.
Authors’ Conclusions
Low molecular weight heparin and NSAIDs appear as
the current best therapeutic options for ST of the legs.
While the available data are too limited to make clear
recommendations, an intermediate dose of LMWH for
at least a month might be advised. Further research is
needed to assess the role of NSAIDs and LMWH, the
optimal doses and duration of treatment, and whether
a combination therapy may be more effective than sin-
gle treatment. Adequately designed and conducted
studies are required to clarify the role of topical and
surgical treatments.
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